Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA May Largely Avoid House Democrats' Investigation Agenda

Executive Summary

Drug pricing hearings likely will involve FDA, but most pressing issue facing agency following midterms may be whether Commissioner Gottlieb will depart.

Related Content

Keeping Up With “The Energizer Bunny”: US FDA Commissioner Gottlieb As A Boss
Opioid Prescribing Guidelines Will Be More Template Than Commandment
Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control
Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018
Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA
Opioid Policy At US FDA: Over-Promising Or Overreacting?
US FDA Preparing For New 'Combination Product Agreement Meetings'
Opioid Blister-Pack Mandate Tops Gottlieb's Agenda With New Authority
US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating
US FDA Commissioner A 'Star' At Davos: Hopefully Not A Bad Omen


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts